Company intelligence / Profile preview
Shaanxi Micot Technology Co., Ltd.
Xi'an, Shaanxi, Chinatracxn.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has multiple products in clinical development, with MT-1002 (a bispecific peptide) in Phase 2 for acute coronary syndromes, MT-2004 in Phase 2 for liver injury, MT-1013 in Phase 2 for hypercalcemia and secondary hyperparathyroidism, and MT-200605 in Phase 1 for ischemic stroke. They recently discovered new anticoagulant reversal agents (theophylline derivatives) for hemorrhagic disorders[6].
- Therapeutic areas
- GastroenterologyHematologyEndocrinologyCardiovascular
- Modalities
- Synthetic peptidesSmall moleculesBiological products
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Shaanxi Micot Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shaanxi Micot Technology Co., Ltd..